Dr. Albert Bourla, Chairman and CEO of Pfizer, said: “With excellent execution in 2025, we delivered a solid financial performance and strengt...
Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovati...
First-ever approved treatment for CDD in China now set for commercial launch through dedicated rare disease platform Tenacia Biopharmaceutical...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and ful...
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER); Impact of VYVANSE® Generics is T...
China’s National Medical Products Administration (NMPA) has approved Seysara®(sarecycline hydrochloride) for the treatment of inflammatory ...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel trea...
BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneo...
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard...
AI's presence in pharma & animal health is rapidly expanding – the global AI pharmaceutical market is expected to grow to tens of billion...
Antibodies Inc., a leading supplier of validated life science research reagents, announced the availability of its Recombinant Guinea Pig RBPMS An...
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), announced the extension of its long-standing stra...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA...
© 2026 Biopharma Boardroom. All Rights Reserved.
